Join Our Newsletter Now
Cancer drugs that have been approved in the United States are often not immediately approved in the United Kingdom and Canada, owing to uncertainty over benefits and harms as well as extremely high prices, two new studies in JAMA Internal Medicine indicate.
The oncology drug approval process of the US Food and Drug Administration (FDA) is “broken,” concludes an accompanying editorial.
“Many cancer drugs come to market in the United States and, eventually, globally at unaffordable prices with massive uncertainty about their benefits and harms,” say the editorialists, Vinay Prasad, MD, MPH, University of California, San Francisco, and Myung Kim, MD, Oregon Health and Science University, Portland, Oregon.
“The US system of approval of drugs with uncertain clinical benefit followed by mandated coverage by Medicare without any ability to negotiate on prices ensures access,” they observe.
“It is less clear that the US system benefits patients with cancer,” they conclude.
In addition, the uptake of these cancer drugs “is often delayed in high-income Western nations because of justified and persistent doubts about value,” they continue.
“We should consider the possibility that our drug policy has negative repercussions for patients with cancer worldwide,” they write.
The negative repercussions of the FDA drug approval process were most evident in the study from Canada. As analyzed by Daniel Meyers, MD, University of Calgary, Alberta, Canada, and colleagues, between 2011 and 2020, the pan-Canadian Oncology Drug Review (pCODR) issued 104 reimbursement recommendations for cancer drugs that were indicated for solid tumours.
“Three-quarters of all submissions received a positive recommendation,” the investigators report. However, more than 92% of those approvals were conditional, most commonly because of serious reservations about the cost-effectiveness of the drug, they note.
Moreover, only half of the cancer drugs recommended by pCODR improved overall survival (OS), and survival gains were usually modest. The median OS was only 3.7 months, and the median progression-free survival (PFS) was only 4.7 months; these rates are not substantially different from those of drugs that received a negative recommendation, Meyers and colleagues point out.
Importantly, almost 40% of cancer drugs that received a positive recommendation from pCODR did not achieve the threshold for substantial clinical benefit, as assessed by the European Society for Medical Oncology–Magnitude of Clinical Benefit Scale.
These results suggest that despite the pCODR framework, which provides reimbursement recommendations based on clinical benefit, cost-effectiveness, and patient-based values, “cancer drugs without meaningful patient benefit continue to be reimbursed in the Canadian market,” the authors conclude.
In the UK study, Avi Cherla, MSc, London School of Economics and Political Science, London, the United Kingdom, and colleagues compared cancer drug indications that received FDA accelerated approval from December 1992 to May 2017 with the same indications in England through August 2019.
Of 93 cancer drug indications that received FDA accelerated approval over the past 25 years, they found that 30 drug indications were not reviewed for coverage by the UK’s National Health Service (NHS). In addition, 12 drug indications were denied authorization or coverage by either European regulators or the National Institute for Health and Care Excellence (NICE) because of insufficient safety, clinical efficacy, or cost-effectiveness data.
Furthermore, NHS coverage of cancer drugs that did receive FDA accelerated approval frequently required additional price concessions, restriction of drug indications to specific patient subgroups, and the collection of additional data. As has been reported, most drug approvals by the FDA are based on surrogate markers, such as tumour shrinkage or delayed tumour growth (PFS), a point that editorialists Prasad and Kim emphasize.
“Surrogate endpoints result in substantial uncertainty regarding the magnitude of clinical benefit (if any exists), which is a key input to a cost-effectiveness calculation,” they point out.
Perhaps most importantly, “the cancer drugs available in England, Canada, and the US are not as good as physicians would hope for patients,” the editorialists write. For example, only 34 of 52 cancer drugs evaluated by NICE showed any survival benefit, and that benefit was at best very modest.
JAMA Intern Med. Published online February 22, 2021. A Canadian study, Abstract; UK study, Full text; Editorial
The study authors have disclosed no relevant financial relationships. Prasad has received grants from Arnold Ventures Research and personal fees from Johns Hopkins Press, Medscape, UnitedHealthcare, New Century Health, and Evercore. He has also received honoraria from medical centres, nonprofit organizations, and professional societies and hosts a podcast called Plenary Session that has Patreon backers.
Heart Disease Narrowing for Women Younger Than 65
THURSDAY, Feb. 25, 2021 (HealthDay News) — For women aged younger than 65 years, the mortality gap between cancer and heart disease is narrowing, according to a study published online Feb. 8 in the European Heart Journal: Quality of Care & Clinical Outcomes.
Safi U. Khan, M.B.B.S., from West Virginia University in Morgantown, and colleagues compared premature heart disease- and cancer-related deaths in women aged younger than 65 years in the United States. The annual percentage changes (APCs) in age-adjusted mortality rates (AAMRs) and years of potential life lost per 100,000 persons were compared.
The researchers found that cancer was a more prevalent cause of premature death than heart disease overall. Between 1999 and 2018, there were decreases in the AAMRs for both cancer (61.9 to 45.6 per 100,000) and heart disease (29.2 to 22.6 per 100,000). The APC in AAMR for cancer decreased consistently over time, while for heart disease, the APC in AAMR declined initially but increased between 2010 and 2018 (0.53), with significant increases in the Midwest, medium/small metros, and rural areas after 2008. The APC in AAMR for heart disease increased in women aged 25 to 34 years (2.24) and 55 to 64 years (0.46) compared with cancer. There was a narrowing in the mortality gap observed between cancer and heart disease, from 32.7 to 23.0 per 100,000.
“If extreme public health measures are not taken to mitigate cardiovascular risk factors, focusing on high-risk groups, heart disease mortality may supersede cancer to become the leading cause of death in young women,” the authors write
The claim: Long-term mask-wearing may cause advanced-stage lung cancer, one study shows
It is well-known by now masks can help prevent the spread of the novel coronavirus. New data from the U.S. Centers for Disease Control and Prevention recommends even better prevention with double masking. But one social media post claims wearing a mask may cause serious harm in the long run.
“Long-Term Mask Use May Contribute to Advanced Stage Lung Cancer, Study Finds,” asserts a Jan. 29 article from BlackListed News, an independent news platform known to publish pseudoscience and conspiracy-related content.
How exactly this alarming condition arises is through the “inhalation of harmful microbes” into the lung that has been “cultivated through prolonged mask-wearing,” writer Phillip Schneider claims.
He also provides quotes from lead author Dr Leopoldo Segal, director of New York University Langone’s Lung Microbiome Program, explaining the scientific basis for these microbes’ destructive effect, and ties the study’s discovery to the larger trend of purported evidence against mask-wearing.
BlackListed News did not return USA TODAY’s request for comment.
Fact check: Masks encouraged on federal lands if distancing isn’t possible
Oral bacteria can lead to poor lung cancer prognosis and progression
The human body is a host to millions of different kinds of microorganisms inhabiting both the skin surface and deep within various organs, such as the gastrointestinal tract. These bacteria, viruses, fungi and other life forms – the microbiome – play a key role in maintaining health and preventing disease. Shifts in the microbiome because of ageing, long-term dieting, stress or pharmaceutical drugs have been linked to conditions like obesity, depression and autoimmune diseases, among many others.
They can even contribute to cancer, as some emerging research has found. Segal’s study particularly looked at how the microbiome within the lungs – previously believed a sterile, microorganism-free environment – plays into the development of lung cancer, a disease afflicting over 2 million people worldwide and responsible for nearly 1.8 million deaths in 2018, according to the World Health Organization.
The study analyzed the lung microbiomes of 83 untreated adult patients with lung cancer and found that patients with advanced-stage lung cancer (stage III to IV) “had greater enrichment of oral commensals in the lung than those who had the early-stage disease (stages 1-3a),” stated a November news release on the study from the American Association for Cancer Research. Oral commensals are simply oral bacteria.
Some of those bacteria are the same ones typically found in the respiratory tract’s lower airways, such as Prevotella and Veillonella, both of which can cause oral infections and mingle with Streptococcus to form dental plaque (in the case of Veillonella).
These oral bacteria were found to be associated with “decreased survival, even after adjusting for tumour stage.” Veillonella, Prevotella and Streptococcus, in particular, were associated with poor prognosis. All three, plus another bacteria making up the mouth’s normal flora, Rothia, were associated with tumour progression.
The study did report that one limitation to its findings – aside from the study size being too small to allow for patient stratification into subgroups – was that since lung microbiomes were sampled before patients undergoing their respective cancer treatments, “changes resulting from treatment could not be assessed.”
Fact check: Posts use 2012 photo of Magic Johnson to falsely claim he donated blood
No correlation of long-term mask-wearing with lung cancer
USA TODAY reviewed the study’s paper published online this month: Nowhere is long-term mask-wearing mentioned or even alluded to.
Segal and another author, Dr James Tsay of NYU’s Grossman School of Medicine, told Reuters their study did not involve long-term mask-wearing, and that, “currently there is no scientific evidence to this misinterpretation of our result.”
The study’s participants were individuals recruited from NYU’s Lung Cancer Biomarker Center between March 2013 and October 2018, before the pandemic. Tsay stated that “since mask-wearing was not common during our study period, it is highly unlikely it is one of the reasons that contribute to our findings.”
“The main source of these bacteria to the lung is the mouth and oropharynx (the part of the pharynx that is behind the mouth) itself,” said Segal, explaining these oral bacteria are in “pretty much every individual” and how much is present depends on oral hygiene and food intake.
In an email to USA TODAY, Schneider, the author of the BlackListed News article, acknowledged it was his personal view “this study suggests that prolonged mask-wearing may breed microbes which contribute to advanced-stage lung cancer.” Schneider did not say whether he verified his inference with the study’s authors but did add a clarification to the article on his website. This revision has not been made to the original BlackListed News article.
Fact check: Masks encouraged on federal lands if distancing isn’t possible
No evidence mask-wearing poses danger to health
Claims regarding whether face masks work against COVID-19, are detrimental to health (causing oxygen reduction or excessive blood carbon dioxide levels) or violate constitutional amendments have been debunked numerous times.
The claim in November alleging people were arriving in intensive care units sick with pneumonia from mask-wearing has also been debunked.
While bacteria and other microorganisms can collect on the inside of a mask, microbiologist Patrick Grant of Florida Atlantic University told CBS Florida affiliate CBS12 that whatever collects does not have the potential to harm unless it is allowed to build up; borrowing someone else’s mask is also ill-advised.
The CDC recommends storing cloth masks properly – either in plastic bags for damp masks, paper bags for dry or clean ones – and washing regularly, making sure to dry thoroughly. Disposable masks should be thrown away after one use.
Fact check: Post distorts WHO’s COVID-19 PCR testing guidelines
Our rating: False
The claim that long-term mask-wearing was found by one study to contribute to advanced-stage lung cancer is FALSE, based on our research. The study, headed by Dr Leopoldo Segal, director of NYU’s Lung Microbiome Program, found patients with advanced-stage lung cancer had greater amounts of oral bacteria in the lungs compared to early-stage patients. The presence of these bacteria was associated with decreased survival, poor prognosis and tumour progression. Nowhere is the impact of long-term mask-wearing or the relationship with lung cancer mentioned or alluded to. The writer of the article making the claim stated that the relationship was his personal view. There is no evidence to suggest masks, the only effective means to prevent COVID-19 transmission, instead cause disease.
Our fact-check sources:
Centres for Disease Control and Prevention, Feb. 10, “Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021”
Media Bias/Fact Check, accessed Feb. 16, “Blacklisted News”
Nature, Jan. 29, 2020, “The complex relationship between drugs and the microbiome”
The New York Times, Sept. 10, 2019, “Seeking an Obesity Cure, Researchers Turn to the Gut Microbiome”
Science Magazine, May 7, 2020, “Meet the ‘psychobiotic: the gut bacteria that may alter how you think, feel, and act”
Nature, Jan. 29, 2020, “Could a bacteria-stuffed pill cure autoimmune diseases?”
Nature, Jan. 29, 2020, “Fighting cancer with microbes”
The Journal of Immunology, June 15, 2016, “The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease”
The World Health Organization, Sept. 12, 2018, “Cancer”
American Association for Cancer Research, Nov. 11, 2020, “The Lung Microbiome May Affect Lung Cancer Pathogenesis and Prognosis”
American Journal of Respiratory and Critical Care Medicine, June 2, 2011, “Topographical continuity of bacterial populations in the healthy human respiratory tract”
Journal of Bacteriology, June 3, 2015, “Interaction between Streptococcus spp. and Veillonella tobetsu ensis in the Early Stages of Oral Biofilm Formation”
Journal of Microbiological Methods, Jan. 10, 2017, “Isolation and identification methods of Rothia species in oral cavities”
Cancer Discovery, Feb. 1, “Lower Airway Dysbiosis Affects Lung Cancer Progression”
Reuters, Feb. 4, “Fact check: No evidence linking masks to oral bacteria and to lung cancer; article refers to the study that did not involve masks”
USA TODAY, Jul. 27, 2020, “Fact check: What’s true and what’s false about face masks?”
CBS12, Nov. 20, 2020, “Bacteria is growing on your mask”
U.S. Centers for Disease Control and Prevention, Oct. 28, 2020, “How to Store and Wash Masks”
Thank you for supporting our journalism. You can subscribe to our print edition, ad-free app or electronic newspaper replica here.
Our fact check work is supported in part by a grant from Facebook.
This article originally appeared on USA TODAY: Fact check: Long-term face mask-wearing does not cause lung cancer
What is Thyroid Cancer?
Thyroid cancer is a disease in which the cells of cancer are found in thyroid glands. The thyroid glands are the lower part of the throat. This is a rare type of cancer. People in their 30s and those over the age of 60 may be infected by this disease. Women are 2 to 3 times more likely to develop it than men.
Types of Thyroid Cancer:
Generally, there are mainly four main types of thyroid cancer which are based on how the cancer cells look under a microscope. They are:
Symptoms of Thyroid Cancer:
If you have the symptoms which are given below please talk to your doctor right away. The symptoms are:
- Pain in the front of the neck and sometimes it travels upward to the ears.
- A lump in the neck, sometimes growing quickly.
- Swelling in the neck.
- Hoarseness or other voice changes that do not go away.
- A constant cough that does not contain due to cold
- Trouble swallowing.
- Trouble breathing.
Many of these symptoms can also be caused by non-cancerous conditions or even other cancer of the neck area.
Remedy of Thyroid Cancer:
Different tests and procedures are used to diagnose thyroid cancer. Which is as follows:
- Physical exam
- Blood tests
- Ultrasound imaging
- Removing a sample of thyroid tissue
- Other imaging tests
- Genetic testing
Most of thyroid cancer can be cured by treatment. Very small thyroid cancer that has a low risk of spreading in the body might not need treatment right away. If the risk risks of thyroid cancer grow then treatment should be initiated. Those are:
- Removing a portion of the thyroid (thyroid lobectomy)
- Removing all or most of the thyroid (thyroidectomy)
- Removing lymph nodes in the neck (lymph node dissection)
- Thyroid hormone therapy
- Radioactive iodine
- External radiation therapy
- Targeted drug therapy
- Injecting alcohol into cancer
- Supportive care